Fda kisqali early breast cancer approval date 2024?

There wasn’t a new FDA approval for Kisqali in early (adjuvant) breast cancer in 2024. The initial FDA approval for the adjuvant indication (HR+/HER2-, node-positive, high‑risk early breast cancer) was in 2023.

If you’d like, I can look up the exact FDA press release date and summarize the labeling specifics (which endocrine therapy it’s approved with, patient population, etc.).